Nishadh Sutaria1, Shiu-Chung Au1,2. 1. Tufts University School of Medicine, Boston, MA, USA. 2. Department of Dermatology, Tufts Medical Center, Boston, MA, USA.
Abstract
BACKGROUND: Systemic and biologic therapies have varying failure rates and survival times in treating psoriasis. OBJECTIVE: We aim to describe the patterns of therapy failure in psoriasis patients. METHODS: A retrospective (January 2009 to May 2018) analysis of 250 psoriasis patients seen at a psoriasis referral center, and 806 treatment courses of several systemic and biologic therapies, was conducted to determine failure rates and survival times for systemic and biologic therapies. RESULTS: Systemic therapies failed more often due to their adverse effects (16.4% vs 7.2%, p < .001). Biologics failed more often due to secondary failure (24.2% vs. 9.3%, p < .001). Biologics had a longer survival time (23.9 ± 22.2 vs. 12.6 ± 15.4 months, p < .001), even with early failures (≤6 months) removed (29.0 ± 22.5 vs. 21.1 ± 16.4 months, p = .014). LIMITATIONS: Tertiary referral center, unreported causes of failure, sample size. CONCLUSIONS: Systemic therapies fail more often due to adverse effects while biologics fail more often due to loss of efficacy. Biologic therapies have longer survival times than systemic therapies.
BACKGROUND: Systemic and biologic therapies have varying failure rates and survival times in treating psoriasis. OBJECTIVE: We aim to describe the patterns of therapy failure in psoriasis patients. METHODS: A retrospective (January 2009 to May 2018) analysis of 250 psoriasis patients seen at a psoriasis referral center, and 806 treatment courses of several systemic and biologic therapies, was conducted to determine failure rates and survival times for systemic and biologic therapies. RESULTS: Systemic therapies failed more often due to their adverse effects (16.4% vs 7.2%, p < .001). Biologics failed more often due to secondary failure (24.2% vs. 9.3%, p < .001). Biologics had a longer survival time (23.9 ± 22.2 vs. 12.6 ± 15.4 months, p < .001), even with early failures (≤6 months) removed (29.0 ± 22.5 vs. 21.1 ± 16.4 months, p = .014). LIMITATIONS: Tertiary referral center, unreported causes of failure, sample size. CONCLUSIONS: Systemic therapies fail more often due to adverse effects while biologics fail more often due to loss of efficacy. Biologic therapies have longer survival times than systemic therapies.